Metabolic Phenotyping During Stress Hyperglycemia in Cardiac Surgery Patients
- Status
- TerminatedStopped: The study was terminated following the Data and Safety Monitoring Board (DSMB) review due to concerns with perioperative use of the study drug.
Results posted - Why it is watched
- non-weight indication: cardiovascular
- Who it enrolls
- age 40 Years to 80 Years; BMI ≥25 required; conditions: Stress Hyperglycemia
- Interventions
- Dulaglutide Injection; Saline Injection
- Conditions
- Stress Hyperglycemia
- Phase and size
- Phase 4 · 28 participants
- Dates
- Start 2019-03-08
Primary completion 2023-05-02 - Sponsor
- Emory University (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Number of Participants With Blood Glucose Levels (BG) > 140 mg/dl During Post Operative PeriodDuring the hospital stay (up to 12 days postoperatively)
02Eligibility
Who can take part
Inclusion Criteria: * Males or females between the ages of 40 and 80 years * Body mass index (BMI) ≥25 * Undergoing elective CABG surgery * No previous history of diabetes or hyperglycemia Exclusion Criteria: * Hyperglycemia (BG\>125 mg/dl or HbA1c \> 6.5%) or previous treatment with antidiabetic agents * Impaired renal function (GFR \< 30 ml/min) or clinically significant hepatic failure * Gastrointestinal obstruction expected to require gastrointestinal suction * Patients with clinically relevant pancreatic or gallbladder disease * Treatment with oral or injectable corticosteroid * Mental condition rendering the subject unable to understand the possible consequences of the study * Pregnancy or breastfeeding at time of enrollment
03Change log
Registry changes
No changes recorded since the trial was added.